DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer
Terminated · Phase 2 · NCT03505710
Conditions: Non-Small Cell Lung Cancer
At a glance
- Research payments reported, 2025
- $321,083
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 181
About the trial
- Sponsor
- Daiichi Sankyo (with Daiichi Sankyo Co., Ltd., AstraZeneca)
- Tested
- Trastuzumab deruxtecan (drug)
- Dates
- Started 2018-05-21; completion 2024-04-17
- Results posted
- Yes
The primary objective of this trial is to evaluate the efficacy of trastuzumab deruxtecan in HER2-overexpressing and/or HER2-mutated advanced NSCLC participants.
From ClinicalTrials.gov, last updated 2025-05-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $321,083 in research payments for this study in 2025 (7 payments).
Products named: Enhertu
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Dipesh Uprety, MD Medical Oncology · Detroit, MI
- Bob T. Li, MBBS, MPH, FRACP Medical Oncology · New York, NY
- Christina S. Baik, M.D. Medical Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Washington $191,057
- Karmanos Cancer Center, MI $69,883
- David H Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center $60,143
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.